Smoking Cessation Intervention for Thoracic Patients
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/14/2018 |
| Start Date: | January 2008 |
| End Date: | April 2012 |
A Pilot Smoking Cessation Study for Newly Diagnosed Lung Cancer Patients
The primary aim of the proposed study is to develop and assess the feasibility of delivering
a smoking cessation intervention to patients undergoing lung surgery that begins before
surgery and continues up to 3 months post-discharge. The secondary aim is to assess smoking
cessation rates 3 months following surgery.
a smoking cessation intervention to patients undergoing lung surgery that begins before
surgery and continues up to 3 months post-discharge. The secondary aim is to assess smoking
cessation rates 3 months following surgery.
This is a pilot study evaluating the feasibility of a cognitive-behavioral smoking cessation
plus Varenicline program, designed specifically for early stage lung cancer patients and
patients with a potential lung cancer diagnosis pre and post-surgery. The study population
will be approximately 80 smokers who have upcoming lung resection surgery scheduled at
Massachusetts General Hospital (MGH) in Boston. A patient will be considered eligible for the
intervention or control group if he or she 1) is scheduled for a lung resection surgery with
either a lung cancer diagnosis or a potential lung cancer diagnosis, and 2) had a cigarette
in the past 2 weeks, 3) is willing to make a pre-surgical quit attempt. Patients will be
excluded from the control group if they are 1) non-English speaking, 2) determined medically
ineligible by their surgeon/oncologist, 3) suffering from psychosis or dementia 4) is
currently on Varenicline has been on Varenicline for more than 3 weeks, or 5) is otherwise
unable to participate in the intervention. Patients will be excluded from the intervention
group if they are 1) non-English speaking, 2) determined medically ineligible by their
surgeon, 3) suffering from psychosis or dementia 4) have been taking Varenicline for longer
than three weeks 5) have been taking Bupropion (for smoking cessation purposes) for more than
three weeks, 6) is otherwise unable to participate in the intervention.
plus Varenicline program, designed specifically for early stage lung cancer patients and
patients with a potential lung cancer diagnosis pre and post-surgery. The study population
will be approximately 80 smokers who have upcoming lung resection surgery scheduled at
Massachusetts General Hospital (MGH) in Boston. A patient will be considered eligible for the
intervention or control group if he or she 1) is scheduled for a lung resection surgery with
either a lung cancer diagnosis or a potential lung cancer diagnosis, and 2) had a cigarette
in the past 2 weeks, 3) is willing to make a pre-surgical quit attempt. Patients will be
excluded from the control group if they are 1) non-English speaking, 2) determined medically
ineligible by their surgeon/oncologist, 3) suffering from psychosis or dementia 4) is
currently on Varenicline has been on Varenicline for more than 3 weeks, or 5) is otherwise
unable to participate in the intervention. Patients will be excluded from the intervention
group if they are 1) non-English speaking, 2) determined medically ineligible by their
surgeon, 3) suffering from psychosis or dementia 4) have been taking Varenicline for longer
than three weeks 5) have been taking Bupropion (for smoking cessation purposes) for more than
three weeks, 6) is otherwise unable to participate in the intervention.
Inclusion Criteria:
A patient is eligible if he/she:
1. Is scheduled for a lung resection surgery with either a lung cancer diagnosis or a
potential lung cancer diagnosis
2. Smoked a cigarette in the past 2 weeks
3. Is willing to make a pre-surgical quit attempt
Exclusion Criteria:
Patients will be excluded from the intervention group if they are:
1. Non-English speaking
2. Determined medically ineligible by their surgeon
3. Suffering from psychosis or dementia
4. Have been taking Varenicline for longer than three weeks
5. Have been taking Bupropion (for smoking cessation purposes) for more than three weeks
6. Is otherwise unable to participate in the intervention.
We found this trial at
1
site
Click here to add this to my saved trials
